|
Compound class:
Antibody
Comment: NP137 (Netris Pharma) is a clinical lead anti-netrin 1 IgG1 monoclonal antibody [1]. It was developed as a novel anti-cancer therapeutic. The netrin 1 epitope recognised by NP137 is 90% homologous to the analogous region in netrin 3, suggesting cross-reactivity, and the potential for NP137 to be deployed against netrin 3-expressing tumours [2]. Antibody binding disrupts the netrin 1/UNC5B interaction.
|
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
